Special youth clinics appear to be an effective means of providing healthcare services to young people who otherwise might not engage with healthcare services. But is building more youth clinics realistic given our resource constraints, or is it better to focus on making ‘normal’ clinics more youth-friendly – or should we be looking beyond clinic-based healthcare services altogether? Tiyese Jeranji investigates.
Broadly neutralising antibodies (bnAbs) are one of the most active and exciting areas in HIV research. Last year Spotlight reported on a “proof of concept” study showing that a specific bnAb can successfully prevent infection with certain strains of HIV. Now, we also have intriguing findings suggesting that bnAbs may have a role to play in the treatment of HIV in children. Elri Voigt reports.
Even though the rate of new HIV infections in young women and adolescent girls remains stubbornly high, provision and uptake of pills that can prevent HIV infection have generally been slow and lagging. One potential solution presented at the recent Conference on Retroviruses and Opportunistic Infections is to provide the pills at schools. Tiyese Jeranji reports.
There is no time to waste in planning the South African rollout of cabotegravir (CAB LA), the long-lasting antiretroviral injection approved for use in the United States in December 2021, say local health experts.
The two vaccines used in South Africa’s vaccination programme, those from Johnson & Johnson and Pfizer/BioNTech, have both been shown to be highly effective against COVID-19, particularly in preventing hospitalisation and death. But protection may wane over time and new variants may or may not render these vaccines less effective. Adele Baleta unpacks what we do and do not know about the potential need for booster shots and surveys some of the studies that will help fill the gaps.
Around one in ten of the over seven million people living with HIV in South Africa are not aware that they have the virus in their bodies. One way to ensure more people are diagnosed more quickly is to make HIV self-tests more widely available. Tiyese Jeranji looks at what HIV Self Testing is, how it is done, and what government policy is on this type of HIV testing.
We know antiretroviral therapy can prevent HIV infection, but can natural biological substances do the same? The results of a recent scientific trial have answered this question: Yes, using broadly neutralising antibodies. But what are broadly neutralising antibodies? How do they work? And when will the average person get access to them? Amy Green breaks down the science.
Local researchers have welcomed impressive phase III findings for the Russian-made Sputnik V vaccine published this week in the Lancet medical journal. It is the sixth COVID-19 vaccine found to be effective in preliminary data from a phase III randomised controlled trial and the fourth to have phase III findings published in a leading medical journal.
The HIV epidemic is far from over and we will not reach key UNAIDS targets and control HIV unless we end HIV-related stigma, argues Prof Linda-Gail Bekker.
Antiretroviral (ARV) injections that may protect women from becoming HIV-positive, if proved to be safe and effective, will be a major step forward in the fight against the HIV pandemic. Siyabonga Kamnqa reports.
The COVID-19 virus is spreading rapidly globally and the race is on for a vaccine to curb the respiratory infection. Adele Baleta unpacks the research and development initiatives underway.
Now is not the time to get stuck in complacency and triumphalism over the gains made in the global HIV/Aids response, says former president of the International Aids Society Prof Linda-Gail Bekker.
